Clinical development of topoisomerase-interactive drugs.
Muggia
F M
FM
Norris Cancer Center, University of Southern California, Los Angeles 90089, USA.
Burris
H A
HA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D019772:Topotecan
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D019772:Topotecan; D011034:Podophyllotoxin; D002166:Camptothecin